{"id":58941,"date":"2026-03-06T16:19:47","date_gmt":"2026-03-06T08:19:47","guid":{"rendered":"https:\/\/flcube.com\/?p=58941"},"modified":"2026-03-06T16:19:48","modified_gmt":"2026-03-06T08:19:48","slug":"roches-xofluza-wins-nmpa-approval-for-pediatric-expansion-oral-suspension-cleared-for-children-under-5-years","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58941","title":{"rendered":"Roche’s Xofluza Wins NMPA Approval for Pediatric Expansion \u2013 Oral Suspension Cleared for Children Under 5 Years"},"content":{"rendered":"\n

Roche<\/strong> (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced that Xofluza (baloxavir marboxil)<\/strong> has received expanded NMPA approval<\/strong> in China, with the oral suspension formulation<\/strong> cleared on March 3, 2026<\/strong> for pediatric patients aged 1 to under 5 years<\/strong> with uncomplicated influenza A and B. This follows the February 13, 2026 approval<\/strong> of Xofluza tablets<\/strong> for patients aged 5 years and older<\/strong>, completing the drug’s age-stratified regulatory pathway in the world’s second-largest pharmaceutical market.<\/p>\n\n\n\n

Regulatory Milestones<\/h2>\n\n\n\n
Approval<\/th>Date<\/th>Formulation<\/th>Patient Population<\/th>Indication<\/th><\/tr><\/thead>
Primary Approval<\/strong><\/td>13\u202fFeb\u202f2026<\/td>Tablets<\/td>Adults + pediatric \u22655 years<\/td>Uncomplicated influenza A\/B<\/td><\/tr>
Expanded Approval<\/strong><\/td>3\u202fMar\u202f2026<\/td>Oral suspension<\/td>Pediatric 1 to <5 years<\/td>Uncomplicated influenza A\/B<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td>\u2014<\/td>\u2014<\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Risk Categories Covered:<\/strong> Both approvals include previously healthy patients<\/strong> and high-risk patients<\/strong> (those with conditions predisposing to influenza-related complications).<\/p>\n\n\n\n

Product Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>Xofluza Profile<\/th><\/tr><\/thead>
Drug Class<\/strong><\/td>First-in-class cap-dependent endonuclease inhibitor<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibits influenza virus replication by targeting polymerase acidic (PA) protein<\/td><\/tr>
Key Advantage<\/strong><\/td>Single-dose oral therapy<\/strong> vs. 5-day oseltamivir (Tamiflu) regimen<\/td><\/tr>
Formulations<\/strong><\/td>Tablets (\u22655 years); Oral suspension (1 to <5 years)<\/td><\/tr>
Onset<\/strong><\/td>Rapid symptom relief; reduces viral shedding duration<\/td><\/tr>
Resistance Profile<\/strong><\/td>Lower resistance potential vs. neuraminidase inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pediatric Value Proposition:<\/strong><\/p>\n\n\n\n